Atara Biotherapeutics (ATRA) Return on Capital Employed (2014 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Return on Capital Employed came in at 43.6% in Q1 2026, down 806.0% YoY from 6.18% in Q1 2025, and down 112.5% on a QoQ basis from 348.89% in Q4 2025.
Atara Biotherapeutics (ATRA) Return on Capital Employed (2014 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 13 years of Return on Capital Employed data on file, last reported at 43.6% in Q1 2026.
- Quarterly Return on Capital Employed fell 806.0% year-over-year to 43.6% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43.6% (down 806.0% YoY) and the FY2025 annual result came in at 72.09%, up 313179.0% from the prior year.
- Return on Capital Employed declined to 43.6% in Q1 2026, from 348.89% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 2561.91% in Q2 2024 to a low of 790.4% in Q4 2023.
- A 5-year average of 257.59% and a median of 43.6% in 2026 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 271543 bps — and 2025, when it sank 253888 bps.
- Tracing ATRA's Return on Capital Employed over 5 years: stood at 95.59% in 2022, then plunged by 727 bps to 790.4% in 2023, then surged by 222 bps to 962.15% in 2024, then plunged by 64 bps to 348.89% in 2025, then plunged by 112 bps to 43.6% in 2026.
- The last three Return on Capital Employed figures came in at 43.6% (Q1 2026), 348.89% (Q4 2025), and 169.42% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | -104.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -104.12% |
| Mar 31, 2026 | -43.60% |
| Dec 31, 2025 | 348.89% |
| Sep 30, 2025 | 169.42% |
| Jun 30, 2025 | 23.03% |
| Mar 31, 2025 | -35.54% |
| Dec 31, 2024 | 962.15% |
| Sep 30, 2024 | 504.91% |
| Jun 30, 2024 | 2,561.91% |
| Mar 31, 2024 | 1,517.68% |
| Dec 31, 2023 | -790.40% |
| Sep 30, 2023 | -210.49% |
| Jun 30, 2023 | -153.52% |
| Mar 31, 2023 | -98.50% |
| Dec 31, 2022 | -95.59% |
| Sep 30, 2022 | -90.42% |
| Jun 30, 2022 | -85.06% |
| Mar 31, 2022 | -105.83% |
| Dec 31, 2021 | -96.38% |
| Sep 30, 2021 | -89.53% |